RobierAAguillon PradaMD
Internal Medicine • Houston, TXCritical Care Medicine, Nephrology
Faculty, Department of Pulmonary and Critical Care Medicine
Dr. Aguillon Prada is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
McGovern Medical School
6431 Fannin St
Houston, TX 77030
Summary
- Dr. Robier Aguillon Prada is an Intensivist and Nephrologist in Houston, TX and is affiliated with The University of Texas Houston McGovern Medical School. He received his medical degree from Industrial University of Santander Faculty of Medicine and has been in practice 14 years. He trained at UCSD, The University of Miami, Duke University and Cleveland Clinic
Education & Training
Cleveland Clinic FoundationFellowship, Critical Care Medicine, 2013 - 2015
Duke University HospitalFellowship, Nephrology, 2011 - 2013
University of Miami/Jackson Health SystemResidency, Internal Medicine, 2008 - 2011
Industrial University of Santander Faculty of MedicineClass of 2003
Certifications & Licensure
TX State Medical License 2021 - 2026
OH State Medical License 2013 - 2023
NC State Medical License 2011 - 2013- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Nephrology
Publications & Presentations
PubMed
- 47 citationsCanakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-1...Calvin C Sheng, Debasis Sahoo, Siddharth Dugar, Robier Aguillon Prada, Tom Kai Ming Wang
Clinical Cardiology. 2020-08-24 - 1441 citationsFGF23 induces left ventricular hypertrophyChristian Faul, Ansel P. Amaral, Behzad N. Oskouei, Ming Chang Hu, Alexis Sloan
The Journal of Clinical Investigation. 2011-11-01 - 383 citationsRituximab Targets Podocytes in Recurrent Focal Segmental GlomerulosclerosisAlessia Fornoni, Junichiro Sageshima, Changli Wei, Sandra Merscher-Gomez, Robier Aguillon-Prada
Science Translational Medicine. 2011-06-01
Journal Articles
- Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, ...Paul C Cremer 1, Antonio Abbate 2, Kristin Hudock 3, Carla McWilliams 4, Jinesh Mehta 5, Steven Y Chang 6, Calvin C Sheng 1, Benjamin Van Tassell 2, Aldo Bonaventura 2..., Lancet Rheumatol . 2021 Jun;3(6):e410-e418, 3/17/2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
